• News
    • News by Region
      • College Station
      • Dallas/Fort Worth
      • El Paso
      • Galveston
      • Lubbock
      • San Antonio
      • Texas Cancer News: What You Need to Know
    • News by Topic
      • Alzheimer’s
      • Biofuels
      • Cancer
      • Cardiovascular
      • Diabetes
      • Genetics
      • Infectious Disease
      • Medical Device
      • Neurology
      • Vaccines
    • News by Institution
      • CPRIT
      • Baylor College of Medicine
      • Rice University
      • Texas A&M
      • Texas Heart Institute
      • UNT Health Science Center
      • UT Arlington
      • UT Austin
      • UT Dallas
      • UTHealth
      • UT MD Anderson Cancer Center
      • UT Medical Branch
      • UT Health Science Center San Antonio
      • University of Texas Southwestern Medical Center
    • Editorial Blog
  • Companies
    • Companies by City
      • Austin
        • Featured in Austin
      • College Station
      • Dallas
      • El Paso
      • Fort Worth
      • Galveston
      • Houston
        • Featured in Houston
      • Lubbock
      • San Antonio
      • Temple
      • Waco
    • Companies by Industry
      • Academic/Research
      • Biofuels
      • BioPharm Insurance
      • Biopharma
      • Biotech
      • Clinical Research
      • Contract Research
      • Cosmeceuticals
      • Diagnostics
      • Environmental
      • Featured
      • Genetics
      • Incubator/Accelerator
      • Legal
      • Manufacturing
      • Medical Devices
      • Pharmaceutical
      • Premium
      • Services
      • Supplements
      • Suppliers
      • Venture Capital
  • Service Providers
    • Services
      • Analytical Chemistry
      • Animal
      • Biochemistry
      • Bioprocess Contract
      • Biorepository
      • Cell Biology
      • Cell Culture
      • Chemistry
      • Clinical Research
      • Construction
      • Consulting
      • Contract Manufacturers
      • Contract Pharma
      • Contract Research
    • Suppliers
      • Biospecimens
      • Lab Equipment
      • Manufacturing
      • Meters
      • Microarrays
      • Microscopes
      • Miscellaneous
      • Molecular Biology
      • Packaging
      • Protein
      • Reagents
      • Research Tools
      • RNAi Technology
      • Safety & Hygiene
      • Sample Prep
      • Software Quality
      • Testing Systems
      • Vacuum Equipment
  • Channels
    • Regional Channels
      • Austin
      • College Station
      • Dallas / Fort Worth
      • El Paso
      • Galveston
      • Houston
      • Lubbock
      • San Antonio
    • Topic Channels
      • Alzheimer’s
      • Autism & Autism Spectrum Disorder: What You Need To Know
      • Autosomal Recessive Disease: What You Need To Know
      • Biofuels
      • Biomarkers: What You Need To Know
      • Biomaterials – Biospecimens
      • Brain Cancer: What You Need To Know
      • Cardiovascular
      • Chagas Disease: What You Need To Know
      • Cancer
      • Clostridium Difficile: What You Need To Know
      • Crohn’s Disease: What You Need To Know
      • Cystic Fibrosis: What You Need to Know
      • Dengue Fever: What You Need To Know
      • Depression
      • Ewing’s Sarcoma: What You Need To Know
      • Genetics
      • H7N9: What You Need To Know
      • Hepatitis B: What You Need To Know
      • Infectious Disease
      • Influenza: What You Need To Know
      • Leukemia: What You Need To Know
      • Liver Cancer: What You Need To Know
      • Lung Cancer: What You Need To Know
      • Medical Device
      • Myocardial Ischemia: What You Need To Know
      • Neglected Tropical Diseases: What You Need To Know
      • Neurology
      • Obesity: What You Need To Know
      • Peter Hotez: What You Need To Know
      • Prostate Cancer: What You Need To Know
      • Quantum Dots: What You Need To Know
      • Secondary Progressive MS: What You Need To Know
      • Spinal Muscular Atrophy: What You Need To Know
      • T-Cells: What You Need To Know
      • 3D Technology: What You Need To Know
      • Triple Negative Breast Cancer: What You Need To Know
      • West Nile Virus: What You Need To Know
  • About
  • Advertise

BioNews-TX

BioNews Texas

  • News
    • News by Region
      • College Station
      • Dallas/Fort Worth
      • El Paso
      • Galveston
      • Lubbock
      • San Antonio
      • Texas Cancer News: What You Need to Know
    • News by Topic
      • Alzheimer’s
      • Biofuels
      • Cancer
      • Cardiovascular
      • Diabetes
      • Genetics
      • Infectious Disease
      • Medical Device
      • Neurology
      • Vaccines
    • News by Institution
      • CPRIT
      • Baylor College of Medicine
      • Rice University
      • Texas A&M
      • Texas Heart Institute
      • UNT Health Science Center
      • UT Arlington
      • UT Austin
      • UT Dallas
      • UTHealth
      • UT MD Anderson Cancer Center
      • UT Medical Branch
      • UT Health Science Center San Antonio
      • University of Texas Southwestern Medical Center
    • Editorial Blog
  • Companies
    • Companies by City
      • Austin
        • Featured in Austin
      • College Station
      • Dallas
      • El Paso
      • Fort Worth
      • Galveston
      • Houston
        • Featured in Houston
      • Lubbock
      • San Antonio
      • Temple
      • Waco
    • Companies by Industry
      • Academic/Research
      • Biofuels
      • BioPharm Insurance
      • Biopharma
      • Biotech
      • Clinical Research
      • Contract Research
      • Cosmeceuticals
      • Diagnostics
      • Environmental
      • Featured
      • Genetics
      • Incubator/Accelerator
      • Legal
      • Manufacturing
      • Medical Devices
      • Pharmaceutical
      • Premium
      • Services
      • Supplements
      • Suppliers
      • Venture Capital
  • Service Providers
    • Services
      • Analytical Chemistry
      • Animal
      • Biochemistry
      • Bioprocess Contract
      • Biorepository
      • Cell Biology
      • Cell Culture
      • Chemistry
      • Clinical Research
      • Construction
      • Consulting
      • Contract Manufacturers
      • Contract Pharma
      • Contract Research
    • Suppliers
      • Biospecimens
      • Lab Equipment
      • Manufacturing
      • Meters
      • Microarrays
      • Microscopes
      • Miscellaneous
      • Molecular Biology
      • Packaging
      • Protein
      • Reagents
      • Research Tools
      • RNAi Technology
      • Safety & Hygiene
      • Sample Prep
      • Software Quality
      • Testing Systems
      • Vacuum Equipment
  • Channels
    • Regional Channels
      • Austin
      • College Station
      • Dallas / Fort Worth
      • El Paso
      • Galveston
      • Houston
      • Lubbock
      • San Antonio
    • Topic Channels
      • Alzheimer’s
      • Autism & Autism Spectrum Disorder: What You Need To Know
      • Autosomal Recessive Disease: What You Need To Know
      • Biofuels
      • Biomarkers: What You Need To Know
      • Biomaterials – Biospecimens
      • Brain Cancer: What You Need To Know
      • Cardiovascular
      • Chagas Disease: What You Need To Know
      • Cancer
      • Clostridium Difficile: What You Need To Know
      • Crohn’s Disease: What You Need To Know
      • Cystic Fibrosis: What You Need to Know
      • Dengue Fever: What You Need To Know
      • Depression
      • Ewing’s Sarcoma: What You Need To Know
      • Genetics
      • H7N9: What You Need To Know
      • Hepatitis B: What You Need To Know
      • Infectious Disease
      • Influenza: What You Need To Know
      • Leukemia: What You Need To Know
      • Liver Cancer: What You Need To Know
      • Lung Cancer: What You Need To Know
      • Medical Device
      • Myocardial Ischemia: What You Need To Know
      • Neglected Tropical Diseases: What You Need To Know
      • Neurology
      • Obesity: What You Need To Know
      • Peter Hotez: What You Need To Know
      • Prostate Cancer: What You Need To Know
      • Quantum Dots: What You Need To Know
      • Secondary Progressive MS: What You Need To Know
      • Spinal Muscular Atrophy: What You Need To Know
      • T-Cells: What You Need To Know
      • 3D Technology: What You Need To Know
      • Triple Negative Breast Cancer: What You Need To Know
      • West Nile Virus: What You Need To Know
  • About
  • Advertise
  • Follow
    • Facebook
    • Twitter
    • Google+
    • Linkedin
    • Pinterest
Entire Lobe Of Lung Removal More Effective Than Partial Resection To Early-Stage Lung Cancer Patients
Home
News

Entire Lobe Of Lung Removal More Effective Than Partial Resection To Early-Stage Lung Cancer Patients

October 16th, 2014 Isaura Santos 1 comments

According to a recent study from The University of Texas MD Anderson Cancer Center, the removal of the entire lobe of the lung in patients with early-stage lung cancer, rather than the partial resection, may offer better overall survival. In addition, stereotactic ablative radiotherapy (SABR) may offer the exact same survival benefit as a lobectomy for some patients. Published in JAMA Surgery, it is the largest population based study ever to review the modalities of modern treatment for early-stage lung cancer.

The American Cancer Society expects that in 2014, 224,210 people in the United States will be diagnosed with lung cancer, of which 159,260 will die from it. Shervin M. Shirvani, M.D., first author of the study, attending radiation oncologist at Banner MD Anderson Cancer Center in Arizona, and an adjunct professor at MD Anderson, says that with the aging baby-boomer population colliding with spiral CT-screening’s acceptance as a screening tool for lung cancer, the diagnosed cases will be much more.

Lung cancer is a typically cancer that is driven by age; it is more frequent in older people. Furthermore, because it is associated with smoking, patients often carry other comorbidities such as chronic obstructive pulmonary disease (COPD), renal failure, and coronary artery disease.

For patients with early-stage disease, there are 3 treatment options: lobectomy, or removal of the entire lobe of lung; sublobar resection, or removal of the part of the lung that contains the tumor; and SABR, a precise form of radiation therapy that usually takes 3 or 5 sessions to be delivered.

“Currently, lung cancer is one of the most common and fatal cancers, and for the foreseeable future it will be one of the major health epidemics our country faces. Yet we don’t have strong evidence-based guidelines for how to best treat the disease — especially when it’s discovered early,” states Shervin M. Shirvani.

Several trials were organized to compare the 3 types of treatment, but there was no participation by patients and physicians and, consequently, none of them reached any conclusions. “In the absence of clinical trials, it was important to analyze observational data from a very large database to compare these three modalities. We wanted to compare lobectomy, the treatment generally thought to be the standard of care, to both the smaller surgery and stereotactic ablative radiotherapy, which does not carry surgical risk, and understand which may be best for this elderly patient population with extensive concurrent illnesses.”

Researchers analyzed the Surveillance, Epidemiology and End Results (SEER) Medicare database looking for patients treated for non-small cell lung cancer (NSCLC) between 2003 and 2009. 9,093 patients were identified, and they all received 1 of the 3 treatments available: lobectomy (7,215 patients, or 79.3 percent); sub lobar resection (1,496 patients, or 16.5 percent); and SABR (382 patients, or 4.2 percent).

Researchers were surprised, finding that the lobectomy was associated with better overall and lung-specific survival when compared to sub lobar resection. “The assumption was that for an elderly patient with a number of co-morbidities, the smaller surgery would be better than a whole lobectomy because there would be fewer surgical complications. Yet, it appears that the ability to eradicate the cancer with the bigger surgery may be more important than minimizing surgical risk,” explained Shirvani.

Patients with similar disease conditions treated with lobectomy and SABR were compared and the two modalities were associated with similar overall survival and lung-cancer specific therefor SABR may be a promising alternative to surgery for patients with very advanced age or with multiple medical problems.

“Clearly, the incidence of early-stage lung cancer will increase dramatically in the next few years, and we need to be prepared to treat patients in the right way — balancing the effectiveness versus risk of treatment in an elderly population,” explained Benjamin Smith, MD, associate professor, Radiation Oncology at MD Anderson, hoping that physicians begin to rethink their thoughts about a smaller surgery being better-suited for this patient population.

Share this article

Next article Second Infected Dallas Health Care Worker Raises Questions About Ebola Protective Protocols, Travel By Exposed Persons
Previous article DNAtrix Completes $20M Funding Round for Glioblastoma Treatment

Isaura Santos

Isaura Santos graduated with a BS in Cell and Molecular Biology from Universidade Nova de Lisboa and a MA in Communication, Culture and Information Technologies from University Institute of Lisbon (ISCTE-IUL). Her professional interests include science communication, public awareness of science and communication of science through entertainment.

Popular Tags

20th annual Vulcan Materials Funshoot 340B 2014 World Stem Cell Summit austin BIG DATA bioaustin biorepositories biospecimens blog Cancer Therapy & Research Center Chemistry Chuck Reed College Station CPRIT CPRIT Foundation crowdfunding cystic fibrosis Dallas DFW drug discount enventure fort worth Funding Galveston GlaxoSmithKline Governor Rick Perry Greatbatch Greg Abbott Health Industry Council of North Texas houston How to Support People With MS Jennifer Stevens lab Medical Device Multiple Sclerosis Multiple Sclerosis Support Obama Obamacare Primary Progressive Multiple Sclerosis san antonio Sante Ventures SB 149 Signs Of MS Texas A&M thbi

Archives

  • Texas’ Only Source For Biotech & Life Sciences News
  • About
  • News
  • Terms of Use
  • Privacy Policy
  • Contact
  • Back to top
© BioNews Services
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more